Category

Archives

VEGFR

VEGFR 2 in vascular smooth muscle cells mediates H 2 S-induced dilation of the rat cerebral basilar artery

12 views | Jan 10 2022

Jinhua Chen et al. found that H2S-induced CBA dilation and reduction of [Ca2+]i in VSMCs occured by acting on VEGFR2. [Read the Full Post]

Activation of inflammasomes by tyrosine kinase inhibitors of vascular endothelial growth factor receptor: Implications for VEGFR TKIs-induced immune related adverse events

14 views | Jan 10 2022

Hideki Imano et al. thought that activation of inflammasomes contributes to the idiosyncratic reactions associated with semaxanib and sorafenib. [Read the Full Post]

Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors

28 views | Jan 05 2022

Yilin Bao et al. found significant correlations of DNA methylation of specific CpG sites with response to the FGFR1/3-selective inhibitors PD 173074 and AZD4547, predominantly within the transcription start site of CCND1. [Read the Full Post]

Using Patient-Derived Xenografts to Explore the Efficacy of Treating Head-and-Neck Squamous Cell Carcinoma With Anlotinib

40 views | Dec 30 2021

Fangling Hu et al. suggested that anlotinib could potentially treat HNSCC. [Read the Full Post]

Safety of Anlotinib Capsules Combined with PD-1 Inhibitor Camrelizumab in the Third-Line Treatment of Advanced Non-Small-Cell Lung Cancer and Their Effect on Serum Tumor Markers

48 views | Dec 30 2021

Yinhua Wang et al. found that application of anlotinib capsules combined with the PD-1 inhibitor (camrelizumab) in the third-line treatment of advanced NSCLC could effectively reduce the levels of serum tumor markers and cancer fatigue degree of patients. [Read the Full Post]

Nintedanib Regulates GRK2 and CXCR2 to Reduce Neutrophil Recruitment in Endotoxin-Induced Lung Injury

279 views | Oct 02 2021

Vincent Yi-Fong Su et al. found that the inhibition of adhesion molecules via the activation of GRK2 and the inhibition of p38 MAPK and CXCR2. [Read the Full Post]

Immunotherapy in Hepatocellular Carcinoma

553 views | Aug 27 2021

Claudia A M Fulgenzi et al. thought that in the absence of predictive biomarkers, choice of immunotherapy over kinase inhibitors would continue to remain an empirical exercise, guided by balancing anti-tumour efficacy with toxicity considerations in the individual patient. [Read the Full Post]

Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target effect for the Bcr-Abl tyrosine kinase inhibitor dasatinib

692 views | Aug 09 2021

Neslihan Büküm et al. demonstrated that dasatinib could synergize with Daun in human cancer cells and enhance its therapeutic effectiveness. [Read the Full Post]

Predictors of Response and Survival to Multikinase Inhibitors in Radioiodine Resistant Differentiated Thyroid Cancer

510 views | Aug 08 2021

Tiziana Feola et al. provided an overview of the predictive factors for the response and survival of sorafenib and lenvatinib in RR-DTC. [Read the Full Post]

YAP/TAZ suppress drug penetration into hepatocellular carcinoma via stromal activation

538 views | Jun 15 2021

Kyungjoo Cho et al. indicated that drug delivery into liver cancer was impaired by YAP/TAZ signaling in tumor cells and subsequent activation of stroma by the signaling. [Read the Full Post]